Review finds selexipag is well tolerated in children

Robyn Kalda
Mar 16
1 min read

A review of 12 studies evaluating selexipag in pediatric patients with pulmonary arterial hypertension found that it improved functional capacity and mPAP, especially when added to existing therapies. About 60% of pediatric patients had side effects, mostly mild.

Read the Pediatric Cardiology article

Recent Posts

Sotatercept might help treat portopulmonary hypertension

Patients with portopulmonary hypertension were not included in clinical trials for sotatercept. This case report found that sotatercept helped one patient with portopulmonary hypertension, who was the

Exercise is safe and effective for PH patients

Researchers conducted a meta-analysis, looking at 13 studies with about 700 participants in total with pulmonary hypertension (PH). They found that exercise improved 6-minute walk distance and was con

In CTEPH, antioxidant enzyme PRDX2 reduces inflammation

A study found that chronic thromboembolic pulmonary hypertensio (CTEPH) patients had significantly more of an antioxidant enzyme (peroxiredoxin 2, or PRDX2) in their bloodstream compared to healthy pa

Comments